search
Back to results

Evaluation of 2 Doses of Intravenous Droperidol in the Prevention of Postoperative Nausea (DIPAVO)

Primary Purpose

Nausea, Vomiting

Status
Terminated
Phase
Phase 4
Locations
France
Study Type
Interventional
Intervention
Droperidol
Sponsored by
University Hospital, Bordeaux
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Nausea focused on measuring Thyroidectomy, Nausea, Vomiting, Droperidol

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Female
  • More than 18 years old
  • Patients scheduled for thyroid surgery
  • Simplified Apfel score ≥ 2
  • ASA score : 1-2
  • Informed consent obtained from the patient
  • Women able to procreate must have a reliable contraceptive method

Exclusion Criteria:

  • Age < 18 years old
  • Male
  • Obesity
  • Has a severe depressive syndrome
  • Pregnancy women
  • Trouble with cardiac rate
  • Alcoholism
  • Contra-indication for Droperidol prescription

Sites / Locations

  • Département d'Anesthésie-Réanimation II ; Groupe Hospitalier Sud, CHU de Bordeaux

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Placebo Comparator

Arm Label

1

2

3

Arm Description

Intravenous injection of 0,625 mg Droperidol, 30 min before the end of anesthesia

Intravenous injection of 2,5 mg Droperidol, 30 min before the end of anesthesia

Intravenous injection of NaCl 9% (Placebo), 30 min before the end of anesthesia

Outcomes

Primary Outcome Measures

No vomiting episode

Secondary Outcome Measures

Light nausea
Control of nausea
Anti-vomiting treatment
Adverse events
Modification of electrocardiograph
- Score of sedation

Full Information

First Posted
March 6, 2007
Last Updated
December 12, 2011
Sponsor
University Hospital, Bordeaux
Collaborators
Prostrakan Pharmaceuticals
search

1. Study Identification

Unique Protocol Identification Number
NCT00445055
Brief Title
Evaluation of 2 Doses of Intravenous Droperidol in the Prevention of Postoperative Nausea
Acronym
DIPAVO
Official Title
Study of Evaluation of the Profile of Efficiency / Tolerance of 2 Doses of Intravenous Droperidol in the Prevention of the Postoperative Nausea and Vomits Related to the Surgery of the Thyroid
Study Type
Interventional

2. Study Status

Record Verification Date
December 2011
Overall Recruitment Status
Terminated
Study Start Date
April 2007 (undefined)
Primary Completion Date
April 2009 (Actual)
Study Completion Date
April 2009 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Bordeaux
Collaborators
Prostrakan Pharmaceuticals

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
In this prospective, randomised, placebo-controlled study, the researchers determined whether 0.625 mg or 2.5 mg of IV droperidol given 30 min before emergence from general anaesthesia reduces the incidence of immediate and delayed post operative nausea and vomiting (PONV) in thyroid surgical female population. Two hundred and forty six female patients receiving general anaesthesia for thyroid surgery received either droperidol 0.625 mg or droperidol 2.5 mg or placebo before emergence.
Detailed Description
Principal Objective : Our study examined one main question: Are there difference in efficacy between droperidol IV 0.625 mg or 2.5 mg for the treatment or prophylaxis of PONV to surgical patient undergoing thyroid surgery when they receive it 30 min before emergence from general anaesthesia? Secondary Objective : comparison of the % of patients in every group: having a complete control of their nausea requiring secondarily the appeal to another anti-emetic treatment in postoperative presenting an Adverse event Compare score of sedation in ach groups Evaluate electrocardiograph Compare the morphine consumption Study design : Prospective, randomized, monocenter, double-blind study Inclusion criteria : Female More than 18 years old Patients scheduled for thyroid surgery Simplified Apfel score ≥ 2 ASA score : 1-2 Informed consent obtained from the patient the women in age of procreate must have a reliable contraceptive method Exclusion criteria : age < 18 years old male obesity present a severe depressive syndrome pregnancy women trouble of cardiac rate alcoholism contra-indication for Droperidol prescription Study plan: three parallel groups will receive 2 different doses of Droperidol or placebo at the end of surgery. Group 1: 0,625mg of Droperidol at the end of surgery Group 2: 2,5mg of Droperidol at the end of surgery Group 3: Placebo at the end of surgery Number of subjects : 246

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Nausea, Vomiting
Keywords
Thyroidectomy, Nausea, Vomiting, Droperidol

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
71 (Actual)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Experimental
Arm Description
Intravenous injection of 0,625 mg Droperidol, 30 min before the end of anesthesia
Arm Title
2
Arm Type
Experimental
Arm Description
Intravenous injection of 2,5 mg Droperidol, 30 min before the end of anesthesia
Arm Title
3
Arm Type
Placebo Comparator
Arm Description
Intravenous injection of NaCl 9% (Placebo), 30 min before the end of anesthesia
Intervention Type
Drug
Intervention Name(s)
Droperidol
Intervention Description
Intravenous injection
Primary Outcome Measure Information:
Title
No vomiting episode
Time Frame
During the first four hours after intervention
Secondary Outcome Measure Information:
Title
Light nausea
Time Frame
24h post operative
Title
Control of nausea
Time Frame
24h post operative
Title
Anti-vomiting treatment
Time Frame
24h post operative
Title
Adverse events
Time Frame
24h post operative
Title
Modification of electrocardiograph
Time Frame
30 min and 120 min after injection
Title
- Score of sedation
Time Frame
24h post operative

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Female More than 18 years old Patients scheduled for thyroid surgery Simplified Apfel score ≥ 2 ASA score : 1-2 Informed consent obtained from the patient Women able to procreate must have a reliable contraceptive method Exclusion Criteria: Age < 18 years old Male Obesity Has a severe depressive syndrome Pregnancy women Trouble with cardiac rate Alcoholism Contra-indication for Droperidol prescription
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Gérard JANVIER, MD
Organizational Affiliation
University Hospital, Bordeaux
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Laure BAUDOUIN, Dr
Organizational Affiliation
University Hospital, Bordeaux
Official's Role
Principal Investigator
Facility Information:
Facility Name
Département d'Anesthésie-Réanimation II ; Groupe Hospitalier Sud, CHU de Bordeaux
City
PESSAC Cedex
ZIP/Postal Code
33604
Country
France

12. IPD Sharing Statement

Citations:
PubMed Identifier
10730546
Citation
Kovac AL. Prevention and treatment of postoperative nausea and vomiting. Drugs. 2000 Feb;59(2):213-43. doi: 10.2165/00003495-200059020-00005.
Results Reference
background
PubMed Identifier
8031342
Citation
Williams OA, Clarke FL, Harris RW, Smith P, Peacock JE. Addition of droperidol to patient-controlled analgesia: effect on nausea and vomiting. Anaesthesia. 1993 Oct;48(10):881-4. doi: 10.1111/j.1365-2044.1993.tb07419.x.
Results Reference
background
PubMed Identifier
12818945
Citation
Gan TJ, Meyer T, Apfel CC, Chung F, Davis PJ, Eubanks S, Kovac A, Philip BK, Sessler DI, Temo J, Tramer MR, Watcha M; Department of Anesthesiology, Duke University Medical Center. Consensus guidelines for managing postoperative nausea and vomiting. Anesth Analg. 2003 Jul;97(1):62-71, table of contents. doi: 10.1213/01.ane.0000068580.00245.95.
Results Reference
background
PubMed Identifier
10389804
Citation
Wang JJ, Ho ST, Lee SC, Liu YC, Liu YH, Liao YC. The prophylactic effect of dexamethasone on postoperative nausea and vomiting in women undergoing thyroidectomy: a comparison of droperidol with saline. Anesth Analg. 1999 Jul;89(1):200-3. doi: 10.1097/00000539-199907000-00036.
Results Reference
background
PubMed Identifier
10875717
Citation
Henzi I, Sonderegger J, Tramer MR. Efficacy, dose-response, and adverse effects of droperidol for prevention of postoperative nausea and vomiting. Can J Anaesth. 2000 Jun;47(6):537-51. doi: 10.1007/BF03018945.
Results Reference
background

Learn more about this trial

Evaluation of 2 Doses of Intravenous Droperidol in the Prevention of Postoperative Nausea

We'll reach out to this number within 24 hrs